Skip to content
Phoenix Biotechnology, IncPhoenix Biotechnology, Inc
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us
Oleander

USFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer.

Posted on August 2007June 2022 by Carlos Torres
06
Aug
This entry was posted in Oleander. Bookmark the permalink.
Phoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center.
Phoenix executes an amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center
Copyright 2023 © Phoenix Biotechnology, Inc. All Rights Reserved. | Terms of Use | Privacy Policy | Cookies Policy
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us